Medium- and long-term recurrence after radioiodine therapy for differentiated thyroid carcinoma with recombinant human thyrotropin: a meta-analysis
IntroductionRadioactive iodine (RAI) is commonly used in the management of differentiated thyroid cancers (DTCs). However, the long-term efficacy and the risk of tumor recurrence associated with it remain unclear. In particular, the comparison between recombinant human thyrotropin (rhTSH) and thyroi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1474121/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850249949339451392 |
|---|---|
| author | Qixian Yao Lili Song Jun Xu Zhongliang Wu |
| author_facet | Qixian Yao Lili Song Jun Xu Zhongliang Wu |
| author_sort | Qixian Yao |
| collection | DOAJ |
| description | IntroductionRadioactive iodine (RAI) is commonly used in the management of differentiated thyroid cancers (DTCs). However, the long-term efficacy and the risk of tumor recurrence associated with it remain unclear. In particular, the comparison between recombinant human thyrotropin (rhTSH) and thyroid hormone withdrawal (THW) in terms of medium- and long-term recurrence rate in DTC patients has not been fully elucidated.MethodsA systematic search was carried out to identify articles comparing medium- and long-term outcomes (> 2 years) based on treatment with either rhTSH or THW. Ten studies, consisting of six randomized controlled trials (RCTs) and four retrospective studies with a total of 2,833 patients, were included in the analysis.ResultsThere was no significant difference in the medium- and long-term recurrence rates between the rhTSH group and the THW group. This was also the case in subgroup analyses of only RCTs or only retrospective studies. The structural incomplete response (SIR) rate was slightly higher in the rhTSH group, but a subgroup analysis of RCTs alone showed no significant difference in SIR between the two groups.DiscussionrhTSH is comparable to THW in achieving successful ablation of residual disease and maintaining low recurrence rates. However, further RCTs are required to investigate whether rhTSH can increase the risk of SIR. |
| format | Article |
| id | doaj-art-69cd44caae394ba39c4bc3b41b61ba1f |
| institution | OA Journals |
| issn | 1664-2392 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-69cd44caae394ba39c4bc3b41b61ba1f2025-08-20T01:58:22ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922024-12-011510.3389/fendo.2024.14741211474121Medium- and long-term recurrence after radioiodine therapy for differentiated thyroid carcinoma with recombinant human thyrotropin: a meta-analysisQixian Yao0Lili Song1Jun Xu2Zhongliang Wu3Department of Surgery, Community Health Service Center of Suzhou Science & Technology Town, Suzhou, Jiangsu, ChinaDepartment of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaDepartment of Rehabilitation, The People’s Hospital of Suzhou New District, Suzhou, Jiangsu, ChinaDepartment of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaIntroductionRadioactive iodine (RAI) is commonly used in the management of differentiated thyroid cancers (DTCs). However, the long-term efficacy and the risk of tumor recurrence associated with it remain unclear. In particular, the comparison between recombinant human thyrotropin (rhTSH) and thyroid hormone withdrawal (THW) in terms of medium- and long-term recurrence rate in DTC patients has not been fully elucidated.MethodsA systematic search was carried out to identify articles comparing medium- and long-term outcomes (> 2 years) based on treatment with either rhTSH or THW. Ten studies, consisting of six randomized controlled trials (RCTs) and four retrospective studies with a total of 2,833 patients, were included in the analysis.ResultsThere was no significant difference in the medium- and long-term recurrence rates between the rhTSH group and the THW group. This was also the case in subgroup analyses of only RCTs or only retrospective studies. The structural incomplete response (SIR) rate was slightly higher in the rhTSH group, but a subgroup analysis of RCTs alone showed no significant difference in SIR between the two groups.DiscussionrhTSH is comparable to THW in achieving successful ablation of residual disease and maintaining low recurrence rates. However, further RCTs are required to investigate whether rhTSH can increase the risk of SIR.https://www.frontiersin.org/articles/10.3389/fendo.2024.1474121/fullrecombinant human thyroid stimulating hormonedifferentiated thyroid carcinomalong-term recurrencethyroid hormone withdrawalradioactive iodine |
| spellingShingle | Qixian Yao Lili Song Jun Xu Zhongliang Wu Medium- and long-term recurrence after radioiodine therapy for differentiated thyroid carcinoma with recombinant human thyrotropin: a meta-analysis Frontiers in Endocrinology recombinant human thyroid stimulating hormone differentiated thyroid carcinoma long-term recurrence thyroid hormone withdrawal radioactive iodine |
| title | Medium- and long-term recurrence after radioiodine therapy for differentiated thyroid carcinoma with recombinant human thyrotropin: a meta-analysis |
| title_full | Medium- and long-term recurrence after radioiodine therapy for differentiated thyroid carcinoma with recombinant human thyrotropin: a meta-analysis |
| title_fullStr | Medium- and long-term recurrence after radioiodine therapy for differentiated thyroid carcinoma with recombinant human thyrotropin: a meta-analysis |
| title_full_unstemmed | Medium- and long-term recurrence after radioiodine therapy for differentiated thyroid carcinoma with recombinant human thyrotropin: a meta-analysis |
| title_short | Medium- and long-term recurrence after radioiodine therapy for differentiated thyroid carcinoma with recombinant human thyrotropin: a meta-analysis |
| title_sort | medium and long term recurrence after radioiodine therapy for differentiated thyroid carcinoma with recombinant human thyrotropin a meta analysis |
| topic | recombinant human thyroid stimulating hormone differentiated thyroid carcinoma long-term recurrence thyroid hormone withdrawal radioactive iodine |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2024.1474121/full |
| work_keys_str_mv | AT qixianyao mediumandlongtermrecurrenceafterradioiodinetherapyfordifferentiatedthyroidcarcinomawithrecombinanthumanthyrotropinametaanalysis AT lilisong mediumandlongtermrecurrenceafterradioiodinetherapyfordifferentiatedthyroidcarcinomawithrecombinanthumanthyrotropinametaanalysis AT junxu mediumandlongtermrecurrenceafterradioiodinetherapyfordifferentiatedthyroidcarcinomawithrecombinanthumanthyrotropinametaanalysis AT zhongliangwu mediumandlongtermrecurrenceafterradioiodinetherapyfordifferentiatedthyroidcarcinomawithrecombinanthumanthyrotropinametaanalysis |